Gene Therapy Market Report 2026

The gene therapy market size has grown exponentially in recent years. It will grow from $16.36 billion in 2025 to $21.46 billion in 2026 at a compound annual growth rate (CAGR) of 31.2%. The growth in the historic period can be attributed to growing prevalence of genetic disorders, advancement in viral vector technology, increasing r&d investments in gene therapy, supportive government policies, rising awareness about rare diseases.

The gene therapy market size is expected to see rapid growth in the next few years. It will grow to $35.61 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to expansion of personalized medicine, emergence of crispr and gene editing therapies, increased private and public funding, integration of ai in gene therapy research, growth in collaborative international clinical trials. Major trends in the forecast period include personalized gene therapy development, crispr and gene editing adoption, regulatory and ethical framework expansion, advanced viral and non-viral vector innovation, collaborative research and clinical trials.

The increasing investment in the healthcare industry is expected to drive the growth of the gene therapy market in the coming years. Healthcare industry investment refers to the allocation of funds toward companies that provide medical services, manufacture medical equipment or drugs, offer medical insurance, or otherwise contribute to the healthcare sector. Such investment plays a crucial role in the gene therapy field, as pharmaceutical companies are investing to strengthen their patent portfolios and secure profitable partnerships. Strategic investments also support the development of new and advanced gene therapy products. For example, in April 2025, according to the American Medical Association, a US-based professional organization, U.S. health spending rose 7.5% to $4.9 trillion, or $14,570 per capita, in 2023, exceeding the 4.6% growth recorded in 2022. Therefore, rising investment in the healthcare industry is contributing to the expansion of the gene therapy market.

Key companies in the gene therapy market are concentrating on developing advanced products, such as adeno-associated virus (AAV) vectors, to improve the precision and effectiveness of gene delivery for treating various genetic disorders. An adeno-associated virus (AAV) vector is a commonly used tool in gene therapy to transport genetic material into cells. For instance, in April 2024, Pfizer Inc., a US-based global biopharmaceutical company, received approval from the Food and Drug Administration (FDA), a US federal agency responsible for public health, for BEQVEZ (fidanacogene elaparvovec-dzkt). BEQVEZ (fidanacogene elaparvovec-dzkt) is a gene therapy designed to treat adults with moderate to severe hemophilia B, a genetic bleeding disorder characterized by a deficiency in clotting factor IX (FIX), which can result in excessive bleeding. The therapy uses an AAV vector to deliver a functional copy of the FIX gene directly to liver cells, enabling the natural production of this essential clotting factor.

In September 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired Decibel Therapeutics, Inc. for an undisclosed amount. This acquisition enables Regeneron to strengthen its gene therapy capabilities, particularly in addressing hearing loss, while supporting its commitment to advancing genetic medicines. Decibel Therapeutics Inc. is a US-based clinical-stage biotechnology company that develops gene therapies to treat hearing and balance disorders.

Major companies operating in the gene therapy market are UniQure NV, REGENXBIO Inc., Bristol-Myers Squibb, BioMarin Pharmaceuticals Inc., Jazz Pharmaceuticals Inc., Biocon, EdiGene Inc, Takeda Pharmaceutical, Daiichi Sankyo Company, Mitsubishi Tanabe Pharma, Merck, Lonza, Pfizer, Cellular Biomedicine Group, GenScript, Albumedix Ltd, Catalent, Freeline Therapeutics, DiNAQOR AG, Vivet Therapeutics, Allergan, Amgen, Biocad, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, AstraZeneca, Bayer AG, Juno Therapeutics, Allogene Therapeutics, Bluebird Bio, Regen BioPharma, Bellicum, BrainStorm Cell Therapeutics, Pluristem, Sanofi.

North America was the largest region in the gene therapy market in 2025. The regions covered in the gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the gene therapy market by increasing costs for imported vectors, lab equipment, and reagents, creating supply chain uncertainties for biopharmaceutical companies. High tariffs particularly affect viral vector manufacturing and oncology therapy segments in regions like north america, europe, and asia-pacific. While costs have risen, some local manufacturers benefit from protective tariffs, encouraging regional production and domestic innovation in gene therapy solutions. Overall, tariffs have created a mixed scenario, with supply chain challenges offset by opportunities for local development.

The gene therapy market research report is one of a series of new reports that provides gene therapy market statistics, including gene therapy industry global market size, regional shares, competitors with a gene therapy market share, detailed gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the gene therapy industry. This gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene therapy is a medical approach that involves altering or replacing defective genes within a person’s cells to treat or prevent diseases. It employs vectors, often viruses, to deliver the corrected genetic material into specific cells. Its main goal is to restore normal cell function and assist in curing or managing genetic disorders.

The primary types of gene therapy are germline therapy and somatic cell therapy. Germline therapy, also called germline gene therapy, involves modifying the genes in germline cells - sperm and egg cells - or their precursors. The various vectors include viral vectors, non-viral vectors, and others, and they are applied in oncological disorders, rare diseases, knee osteoarthritis, and neurological conditions. This therapy is utilized across multiple sectors, including biopharmaceutical companies, research institutes, and other end users.

The gene therapy market includes revenues earned by entities by replacing a disease-causing gene with a healthy copy of the gene and inactivating a disease-causing gene that is not functioning properly. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.